United States · Platforms & data · Finviz

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans

Published by Finviz · United States 3 d ago

Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in…

Read the full article on Finviz Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finviz.com)

Also worth reading

MarketBeat

30,000 Shares of Truist Financial Corporation $TFC Bought by Fortitude Financial LLC

Seeking Alpha

Rocky Mountain Chocolate Factory outlines strategic alternatives after $6.6M Durango sale-leaseback and $2M loan

The Motley Fool

Pre-IPO Anduril Stock Climbs 50% in 5 Months

MarketWatch

Blood clots are ‘incredibly common,’ even for pro athletes like Jalen Hurts. Here’s what to know.

Investing.com

Earnings call transcript: Zions Bancorporation tops Q3 2026 EPS forecast

CNBC